Table 2.
Time‐dependent characteristics according to the treatment measured during the follow‐up, starting from the 90° day after discharge
| LB/ICS regular use | LB/ICS occasional use | LB regular use | LB occasional use | Respiratory drugs other than LB | Total days | |
|---|---|---|---|---|---|---|
| 13.0% | 45.7% | 12.5% | 11.1% | 17.5% | 10 496 932 | |
| Regular use of | ||||||
| Statins | 16.3 | 16.6 | 12.8 | 14.6 | 14.6 | 15.5 |
| Antihypertensives | 76.4 | 76.0 | 74.6 | 76.3 | 78.2 | 76.3 |
| Cardiac therapies | 83.8 | 78.1 | 77.6 | 77.0 | 76.1 | 78.3 |
| Proxy of gravity | ||||||
| Moderate exacerbation | 31.4 | 32.1 | 27.1 | 22.2 | 23.2 | 28.7 |
| Severe exacerbation | 19.7 | 19.6 | 20.4 | 15.6 | 10.6 | 17.7 |
| Cardiovascular hosp | 8.6 | 15.8 | 12.7 | 13.8 | 13.6 | 13.9 |
Note: Figures represent the proportion of days spent in the follow‐up period.